Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ACRV

Acrivon Therapeutics Inc

Apr 26 • 04:00PM ET

8.46

Dollar change -0.01
Percentage change -0.12	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWN VXF SCHA CNCR VTWO IWC VTWV RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	32.95%	Shs Outstand	22.52M	Perf Week	-9.90%
Market Cap	261.16M	Forward P/E	-	EPS next Y	-2.80	Insider Trans	30.09%	Shs Float	20.70M	Perf Month	30.86%
Income	-60.39M	PEG	-	EPS next Q	-0.86	Inst Own	62.08%	Short Float	4.95%	Perf Quarter	121.47%
Sales	0.00M	P/S	-	EPS this Y	-4.28%	Inst Trans	-	Short Ratio	1.35	Perf Half Y	58.13%
Book/sh	5.38	P/B	1.57	EPS next Y	1.96%	ROA	-37.80%	Short Interest	1.03M	Perf Year	-32.43%
Cash/sh	4.13	P/C	2.05	EPS next 5Y	-	ROE	-41.41%	52W Range	3.19 - 14.30	Perf YTD	71.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-48.33%	52W High	-40.84%	Beta	1.44
Dividend TTM	-	Quick Ratio	9.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	165.20%	ATR (14)	1.17
Dividend Ex-Date	-	Current Ratio	9.75	EPS Y/Y TTM	-83.06%	Oper. Margin	0.00%	RSI (14)	51.81	Volatility	13.40% 14.28%
Employees	58	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.22
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	-101.64%	Payout	-	Rel Volume	0.36	Prev Close	8.47
Sales Surprise	-	EPS Surprise	-18.13%	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	757.92K	Price	8.46
SMA20	-2.07%	SMA50	30.50%	SMA200	17.73%	Trades		Volume	276,263	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$14
Dec-15-23	Resumed	Jefferies	Buy	$17 → $12
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform	$25
May-08-23	Initiated	BMO Capital Markets	Outperform	$25
Apr-27-23	Initiated	Ladenburg Thalmann	Buy	$22
Apr-20-23	Initiated	H.C. Wainwright	Buy	$24
Dec-12-22	Initiated	Piper Sandler	Overweight	$25
Dec-12-22	Initiated	Jefferies	Buy	$17
Dec-12-22	Initiated	Cowen	Outperform

Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire)
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire)
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
05:31AM	Loading…
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
08:00AM	Loading…
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)
Jun-29-23 04:49PM	7 Up-and-Coming Stocks to Buy for the Next Decade (InvestorPlace)
04:00PM	Loading…
Jun-22-23 04:00PM	Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors (GlobeNewswire)
Jun-02-23 08:00AM	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.77%
08:00AM	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer (GlobeNewswire)
May-07-23 08:17AM	We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-25-23 08:00AM	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-24-23 08:00AM	Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference (GlobeNewswire)
Mar-28-23 08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 08:00AM	Acrivon Therapeutics to Participate on a Panel at Cowens 43rd Annual Health Care Conference (GlobeNewswire) +23.94%
Feb-15-23 05:40AM	Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this year (Simply Wall St.)
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-22-23 03:31PM	13 Cheap New Stocks To Buy (Insider Monkey)
Nov-14-22 10:16PM	Acrivon Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 11 '24	Buy	8.50	2,353,000	20,000,500	5,360,858	Apr 15 08:53 AM
Chione Ltd	10% Owner	Jun 26 '23	Sale	12.93	16	207	3,848,632	Jun 28 03:47 PM
Holm-Jorgensen Rasmus	Chief Financial Officer	Jun 16 '23	Option Exercise	3.63	9,500	34,485	29,530	Jun 20 05:21 PM
Chione Ltd	10% Owner	Jun 15 '23	Sale	12.14	2,056	24,960	3,848,648	Jun 20 05:15 PM
Chione Ltd	10% Owner	Jun 14 '23	Sale	12.13	893	10,832	3,850,704	Jun 14 06:33 PM
Chione Ltd	10% Owner	Jun 13 '23	Sale	12.30	3,000	36,900	3,851,597	Jun 14 06:33 PM
Chione Ltd	10% Owner	Jun 12 '23	Sale	12.34	2,000	24,680	3,854,597	Jun 14 06:33 PM
Devroe Eric	Chief Operating Officer	Jun 05 '23	Option Exercise	1.04	9,225	9,594	62,883	Jun 06 04:15 PM
Blume-Jensen Peter	President and CEO	May 31 '23	Option Exercise	3.88	33,605	130,387	2,403,702	Jun 01 08:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRV

Acrivon Therapeutics Inc

Upgrade your FINVIZ experience